Alcon acquires Neurotech for $550M, adding rare eye disease drug
Tweet Send to a Friend
Alcon (SIX/NYSE: ALC) has acquired Neurotech Pharmaceuticals, Inc. for $550 million, gaining ownership of ENCELTO, the first FDA-approved treatment for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




